points (p = 0.007) lower pain score than non-duloxetine-treated patients among individuals who had any opioid use during the 12-month post-index period. CON-CLUSIONS: Among similar VA patients with MDD, patients treated with duloxetine were associated with lower opioid use than those treated with other antidepressants. Among individuals with any opioid use over the 12-month post-index period, duloxetinetreated patients had better pain scores than non-duloxetine-treated patients. Although not approved for use in pediatrics, hydroxyurea has been shown to decrease painful vaso-occlusive events and hospitalizations (HU) in children with sickle cell disease (SCD), a genetic hematologic disorder primarily affecting people of African descent. However, few data exist on the use of HU, and adherence to treatment, in real-world settings. This study assessed the extent to which children with SCD are adherent with prescribed HU therapy and the association between HU adherence and economic outcomes in this population in a real-world setting. METHODS: Insurance claims of North Carolina Medicaid program enrollees (June 1999-August 2008 were analyzed. Inclusion criteria were ≥1 claims with a diagnosis for SCD (i.e., ICD-9-CM 282.6, 282.6x), ≥2 HU prescriptions in the year following HU initiation, ≤18 years old at the time of HU initiation, and continuous Medicaid enrollment for ≥12 months prior to and following HU initiation. Adherence was measured using the medication possession ratio (MPR), with MPR > 0.8 considered adherent. Multivariable models were estimated to assess the association between HU adherence and economic outcomes (e.g., inpatient costs) in the fi rst year of HU therapy. RESULTS: A totla of 159 subjects (55% female, mean age [SD] 11.3 [4.4] years) met all inclusion criteria. The mean MPR was 0.63, with 41% of subjects adherent. Multivariable models revealed that in the year following HU initiation, adherence was associated with a reduction in all-cause (-$3.695, p = 0.0003) and SCD-related (-$3.002, P < 0.0001) total, inpatient (-$2172, p = 0.001; -$1815, P < 0.0001, respectively), ER (-$314, P < 0.0001; -$202, p = 0.002, respectively), outpatient (-$951, P < 0.0001; -$541, p = 0.005, respectively), and vaso-occlusive event-related (-$3639, P < 0.0001) costs, and an increase in all-cause (+$239, p = 0.014) and SCD-related pharmacy (+$198, P < 0.0001) costs. CONCLUSIONS: Adherence to HU among pediatric SCD patients may be suboptimal and improving adherence to HU therapy among these patients may reduce the economic burden of the illness.
PSY18 DIRECT MEDICAL COSTS OF LIQUID INTRAVENOUS IMMUNOGLOBULINS IN CHILDREN, ADOLESCENTS AND ADULTS IN SPAIN
Darba J 1 , Restovic G 2 , Kaskens L 2 , de Agustin T 3 1 Universitat de Barcelona, Barcelona, Spain; 2 BCN Health, Barcelona, Spain; 3 CSL Behring, Esplugues de Llobregat, Spain OBJECTIVES: The aim of this study is to determine health care resource utilization and direct medical costs in patients treated with intravenous immunoglobulins (IVIGs) in Spain in 2009. METHODS: A cost-of-illness analyses was performed to estimate direct medical annual costs of patients treated with IVIGs. Prevalence data was obtained from the Spanish Primary Immunodefi ciency registry. a semi-structured questionnaire was used to collect data on health care resource utilization and target population distribution. Inpatient and outpatient costs were considered from the perspective of the public health care system. Hospital costs considered were ambulatory-, ward-, premedication-, drug-and administration costs. All costs referred to 2009. In medical practice, IVIG doses depend on a patient's weight and age. Therefore separate analyses were conducted for children and adolescents vs. adults. RESULTS: Patients with replacement therapy were estimated to be 4192 (724 children and adolescents vs. 3450 adults) for 2009. Patients with immunomodulation were estimated to be 1378 (244 children and adolescents vs. 1134 adults) and patients with an allogeneic bone marrow transplantation were estimated at 172 (30 children and adolescents vs. 142 adults ). Mean annual costs for children and adolescents were c6283 with Privigen, c6292 with Kiovig, c6946 with Flebogamma and c6559 with Octagamocta. For adults estimations were c17,078 with Privigen, c17,103 with Kiovig, c18,095 with Flebogamma and c17,423 with Octagamocta. CONCLUSIONS: Direct medical costs for IVIGs were estimated to be c6.9 million for children and adolescents and c84.8 million for adult patients. Drug costs represented 94% of the total direct medical costs. In the context of limited health care resources, the choice for a certain IVIG treatment depends on individual patient characteristics and cost considerations. ) was strongly associated with duloxetine initiation. Patients comorbid with anxiety, cerebrovascular disease, or substance abuse were 1.08 (95% CI: 1.40-3.08), 0.44 (95% CI: 1.01-2.07), and 1.11 (95% CI: 1.10-4.03) times more likely to initiate duloxetine, respectively. Prior opioid users were 1.47 (95% CI: 1.02-2.12) times as likely to initiate duloxetine as those with no prior opioid use. Patients with self-reported severe pain were 1.66 (95% CI: 1.11-2.50) times as likely to initiate duloxetine as those with no reported pain. CONCLUSIONS: DPNP patients in the VA health care system who initiated duloxetine appeared to have prior SOC use, more comorbid conditions, prior substance abuse or opioid use, and higher pain level.
PSY19 PREDICTORS OF DULOXETINE TREATMENT INITIATION AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN IN SOUTH CENTER VETERANS AFFAIRS HEALTH CARE NETWORK IN THE UNITED STATES

PSY20 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS COSTLY FOR THE HEALTH CARE SYSTEM AND WORKPLACE: A SYSTEMATIC LITERATURE REVIEW
Doria A 1 , Grandfi ls N 2 , Maurel F 2 , Rudge H 3 1 University of Padova, Padova, Italy; 2 IMS Health, Paris, France; 3 GlaxoSmithKline, Uxbridge, Middlesex, UK OBJECTIVES: To summarise the state of knowledge of the economic impact of SLE and to gather information to implement a European study on costs of SLE care. METHODS: A systematic review of the literature was undertaken in the ECONLIT, EMBASE, Medline and EMBR databases for full papers relating to the objectives. Key words included SLE, cost, resource, economic, productivity, absenteeism, employment and work disability. Papers were excluded if they were not in English, French, Spanish, Italian or German language. RESULTS: Thirty relevant research papers (relating to 13 different studies) were included. These studies were conducted in Canada, China, Germany, UK and US and used retrospective and prospective methods. Data were mainly obtained from the hospital care setting over a one-year study period. The main resources reported were physician and emergency visits, as well as inpatient hospital stays (of which SLE fl ares and infections were the main causes). Annual direct costs (converted to December 2009 Euros) ranged from c2,879 (Canada) to c14,873 (US), with indirect costs of c1,214 (US/UK/Canada, friction method) to c45,668 (US, labour market activity method). Indirect costs accounted for at least 38% of the total costs when both market and non-market work was valued. Higher disease activity was reported as a predictor of higher direct and indirect costs. Greater damage, more fl ares and nephritis were also found to predict higher direct costs whilst worse physical and/ or mental status predicted higher indirect costs. Only one study focussed on the cost of fl ares. CONCLUSIONS: SLE is costly for the health care system and workplace. However, there is a lack of data on the cost of SLE fl ares and little recent European data relating to the cost of SLE care. HGS/GSK funded.
PSY21 THE IMPACT OF COMORBIDITY ON INFLAMMATORY BOWEL DISEASE HEALTH COSTS
Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy; 2 Apulia Regional Epidemiological Observatory, Foggia, Italy; 3 Apulia Regional Epidemiological Observatory, Bari, Italy OBJECTIVES: To quantify the direct costs (hospitalizations and prescription drugs) of the caring strategies for the Infl ammatory Bowel Disease (IBD). METHODS: All cases of the major types of IBD, Crohn's disease (CD) and ulcerative colitis (UC), occurred in Apulia between 2002 and 2006 were in the study. The patients were identifi ed through a record linkage procedure among three different regional health databases. Multivariate Poisson regression accounting for over-dispersion was used to assess the average annual direct costs per person. Results were reported, separately for the two diseases, as Incidence Rate Ratios (IRR) with 95% confi dence intervals. RESULTS: The cohort consisted of 2,700 cases of CD and 4902 cases of UC. We estimated the average annual costs per person in patients with CD to be equal to 7,153 Euros for hospitalizations and to c2107 for prescription drugs. In patients with UC the average annual costs per person was of c6317 and c2277 for hospitalizations and prescription drugs, respectively. Surgical to medical DRGs ratio for both diseases was 1:5 and the ATC codes relative to intestinal anti-infl ammatory, proton pump inhibition, anti-infl ammatory/anti-rheumatic and corticosteroids products, represented the 40% of all prescriptions. Overall, the analyses showed, both for DC and CU, that the Charlson Comorbidity Index (CCI) was the only variable associated with the direct costs i.e. a signifi cant increase in the costs (p-value < 0.0001) was found according to the severity of the CCI. In particular, it was noted that a worse clinical condition before disease onset (CCI before index date) was predictive of larger costs especially
